Skip to content
CompanySight
Company No. 09758933 · Incorporated 2 Sep 2015

Dnae Oncology Limited

Registered name: DNAE ONCOLOGY LIMITED

Part of Dnae Group Holdings Limited group

Dnae Oncology Limited made £0 revenue and a £215k loss in the year to 31 Dec 2024.

Dnae Oncology Limited’s revenue was £0 in the year to 31 Dec 2024, with a loss of £215k and 0 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 2 years of its filed accounts.

Full P&L filedSection M · Professional, scientific and technical activitiesSIC 72110Research and experimental development on biotechnology
Status
Active
Location
London, London
Age
11 yrs · since 2015
Type
Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2024

Key figures

Small team
Revenue
£0
Growth —
Profit
−£215k
Growth —
Profit margin
—
 
Employees
0
Change —
Profit / employee
—
 
Profitable streak
0yrs
Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

2 filed years

Financial history

Multi-year financials, oldest to newest
Year to31 Dec 202331 Dec 2024
DisclosureFull P&LFull P&L
Profit & loss
Revenue (turnover)£0£0
Cost of sales£0£0
Gross profit£0£0
Operating profit£0£0
Profit before tax−£215k−£215k
Profit after tax−£215k−£215k
Profit (best available)−£215k−£215k
Employees (average)00
Ratios
Profit margin——
Balance sheet — indirect signals, not revenue
Cash at bank£0£0
Net assets−£5.6m−£5.9m
Fixed assets£0£0
Current assets£0£0
Debtors£0£0
Deferred income£0£0
SourceFullAccounts · bulk data Nov 2025FullAccounts · bulk data Nov 2025
Derived from the latest filing

How the business works

Profit margin
—
Profit ÷ revenue.
Gross margin
—
Gross profit ÷ revenue. High for software and services.
Revenue per employee
—
Revenue ÷ average employees.
Profit per employee
—
Profit ÷ average employees.
Cash conversion
—
Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue
—
Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue
—
Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue
—
Money owed by customers. Low = customers pay quickly.
Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets
—
Now −£5.9m
Cash at bank
—
Now £0
Headcount
—
Now 0
Deferred income
—
Now £0
Fixed assets
—
Now £0

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

  1. Dnae Group Holdings Limitedultimate parent75–100%
  2. Dnae Oncology Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (1)

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Latest figures from FullAccounts for the year to 31 Dec 2024 (profit −£215k), from the Companies House accounts bulk data published Nov 2025. Spotted an error? Request a correction.

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.